SIRT1/Nrf2 and PI3K/AKT signaling pathways are two of the key network pathways in which sotagliflozin exhibits additional therapeutic benefits when used to modify the pathophysiology of liver fibrosis. Here, SIRT1 is linked to Hepatic fibrosis.